Literature DB >> 12944607

Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging.

Marc R Engelbrecht1, Henkjan J Huisman, Robert J F Laheij, Gerrit J Jager, Geert J L H van Leenders, Christina A Hulsbergen-Van De Kaa, Jean J M C H de la Rosette, Johan G Blickman, Jelle O Barentsz.   

Abstract

PURPOSE: To evaluate which parameters of dynamic magnetic resonance (MR) imaging and T2 relaxation rate would result in optimal discrimination of prostatic carcinoma from normal peripheral zone (PZ) and central gland (CG) tissues and to correlate these parameters with tumor stage, Gleason score, patient age, and tumor markers.
MATERIALS AND METHODS: Of 58 patients with prostatic carcinoma, 36 were included for analysis. Patients underwent MR imaging at 1.5 T with an endorectal-pelvic phased-array coil and subsequently underwent prostatectomy. A T2-weighted turbo spin-echo sequence, an intermediate-weighted sequence, and a fast T1-weighted gradient-echo sequence (seven sections in 2.03 seconds) during bolus injection of 0.1 mmol gadopentetate dimeglumine per kilogram of body weight were performed. Contrast agent concentration-time curves were obtained for prostatic carcinoma and normal PZ and CG tissue by using whole-mount sections to guide placement of regions of interest. Onset time, time to peak, peak enhancement, relative peak enhancement, washout, and T2 relaxation rates were calculated. Multivariate receiver operating characteristic analysis was performed with and without relative peak enhancement.
RESULTS: Results of multivariate receiver operating characteristic analysis showed that relative peak enhancement demonstrated the highest area under the receiver operating characteristic curve (AUC) in the PZ and the CG (AUC = 0.93, 0.82). Results of multivariate analysis without relative peak enhancement showed that relative peak enhancement in the PZ and washout in the CG demonstrated the highest AUC (AUC = 0.9, 0.81). Pearson correlation coefficients between the dynamic parameters or T2 relaxation rates in carcinoma and the tumor stage, Gleason score, patient age, and tumor markers ranged between 0.02 and 0.44.
CONCLUSION: The optimal parameter for discrimination of prostatic carcinoma in the PZ and CG was relative peak enhancement. If relative peak enhancement was not used, then peak enhancement was optimal in the PZ, and washout was optimal in the CG. Poor-to-moderate correlation was present between the dynamic parameters or T2 relaxation rate in carcinoma and the tumor stage, Gleason score, patient age, tumor volume, and prostate-specific antigen. Copyright RSNA, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944607     DOI: 10.1148/radiol.2291020200

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  83 in total

1.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.

Authors:  B Nicolas Bloch; Elizabeth M Genega; Daniel N Costa; Ivan Pedrosa; Martin P Smith; Herbert Y Kressel; Long Ngo; Martin G Sanda; William C Dewolf; Neil M Rofsky
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

2.  Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation.

Authors:  Kazuhiro Katahira; Taro Takahara; Thomas C Kwee; Seitaro Oda; Yasuko Suzuki; Shoji Morishita; Kosuke Kitani; Yasuyuki Hamada; Mitsuhiko Kitaoka; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2010-07-18       Impact factor: 5.315

3.  Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy.

Authors:  Piotr Kozlowski; Silvia D Chang; Ran Meng; Burkhard Mädler; Robert Bell; Edward C Jones; S Larry Goldenberg
Journal:  Magn Reson Imaging       Date:  2010-04-13       Impact factor: 2.546

Review 4.  Diffusion weighted imaging in prostate cancer.

Authors:  Cher Heng Tan; Jihong Wang; Vikas Kundra
Journal:  Eur Radiol       Date:  2010-10-09       Impact factor: 5.315

Review 5.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 6.  Prostate MR imaging at high-field strength: evolution or revolution?

Authors:  Olivier Rouvière; Robert P Hartman; Denis Lyonnet
Journal:  Eur Radiol       Date:  2005-09-10       Impact factor: 5.315

7.  Contrast-enhanced ultrasound imaging of prostate cancer.

Authors:  Ethan J Halpern
Journal:  Rev Urol       Date:  2006

8.  MR-compatible assistance system for punction in a high-field system: device and feasibility of transgluteal biopsies of the prostate gland.

Authors:  Stephan Zangos; Christopher Herzog; Katrin Eichler; Renate Hammerstingl; Andreas Lukoschek; Stefanie Guthmann; Bernd Gutmann; Uwe Joseph Schoepf; Phillip Costello; Thomas J Vogl
Journal:  Eur Radiol       Date:  2006-10-10       Impact factor: 5.315

9.  3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.

Authors:  Nazanin Hajarol Asvadi; Sohrab Afshari Mirak; Amirhossein Mohammadian Bajgiran; Pooria Khoshnoodi; Pornphan Wibulpolprasert; Daniel Margolis; Anthony Sisk; Robert E Reiter; Steven S Raman
Journal:  Abdom Radiol (NY)       Date:  2018-11

10.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.